1 a thiamine analogue having a chloroethyl group in place of the hydroxyethyl group in the thiazole moiety, was reported prophylactically effective against coccidiosis in chickens (Inoue et al., 1967; Taniguchi et al., 1969; Matsuzawa et al., 1970) . Coccidiosis may be controlled by the incorporation of Beclotiamine naphthalene disulfonate (NDS) in finished feeds at the 0.0125% level.
The present experiment was undertaken to determine the Beclotiamine residues in tissues and eggs following continuous feeding of Beclotiamine to chickens or laying hens. For the purpose, a sensitive method for the estimation of Beclotiamine in tissues and eggs was established. The effect of Beclotiamine on the total thiamine levels in the liver and on performance of the chickens was also examined. minutes and repeat extraction with 10 ml. of 0.1 N HC1. Combine acidic extracts and adjust to pH 4.5 by the addition of 2 M sodium acetate. Add 3 ml. of 10% Takadiastase solution and a few drops of toluene, and keep overnight at 37°C. (This enzyme digestion step may be omitted when only Beclotiamine was determined). Add 5 ml. of 30% metaphosphoric acid to the enzyme digested solution and centrifuge at 3,000 r.p.m. for 15 minutes, and discard the precipitate. Adjust the supernatant solution to pH 4.5 by the addition of 2 M sodium acetate. Add the extract to a Decalso column (0.6 cm. X 5 cm.), which was previously washed with about 200 ml. of water, and allow it to pass slowly through the Decalso column. Discard the nitrate. Wash the column with about 60 ml. of hot water, discarding the washings. Add 10 ml. of hot 25% KC1 solution in 0.1 N HC1 to the column to elute Beclotiamine and thiamine, collecting the effluent solution.
(b) Egg yolk. Carefully break egg to avoid rupturing yolk sac and separate as much of egg white from yolk as possible. Wash yolk in running water to remove most of remaining egg white. Dry yolk on absorbent paper, break yolk sac, and pour yolk into bottle. Weigh 2 g. of egg yolks into a glass-stoppered test tube followed by the addition of 3 ml. of 0.1 N HC1 and 15 ml. of ethyl ether. Shake the tube vigorously, let stand for 10 minutes, and then centrifuge at 2,500 r.p.m. for 1 minute. Discard the ether layer and repeat extraction twice with 10-ml. portions of ethyl ether. The defatted sample was extracted as described in the tissue procedure. Egg white was analyzed in the same procedure as tissue.
Determination. The proposed fluorometric method for the determination of Beclotiamine is based on the conversion of Beclotiamine (I) to chlorothiochrome (II) by a reaction analogous to the oxidative production of thiochrome from thiamine ( Fig.  1 ). Chlorothiochrome could be isolated from thiochrome by difference in their solubilities in chloroform and water: chlorothiochrome was very soluble in chloroform (more than 100 mg./ml.), while thiochrome was only slightly soluble (0.79 mg. /ml.). In water, thiochrome was more soluble (1.33 mg./ml.) than chlorothiochrome (0.54 mg./ml.) at pH 7.0. Thus, when a mixture of chlorothiochrome and thiochrome in water was extracted with chloroform, chlorothiochrome was preferentially transferred to chloroform layers. Thiochrome, which was extracted into the chloroform, was removed by washing with water. Chlorothiochrome showed similar fluorescence properties to thiochrome: fluorescence maximum in chloroform were for chlorothiochrome at 413 m[^. and for thiochrome at 416 m;j.. with monochromatic light of 360 mjj.. as the excitation source. Fluorescence intensity of chlorothiochrome was 1.45-fold higher than that of thiochrome in chloroform in molar basis.
The determination procedure is as follows: pipet 5 ml. of the effluent solution from the Decalso column into a 15 ml. brown glass-stoppered tube. To the tube add 1 ml. of alkaline potassium ferricyanide solution (a mixture of 3 parts of 1% K 3 Fe(CN) 6 and 97 parts of 30% NaOH), mix, and let stand for 2 minutes. Add 5 ml. of chloroform and shake vigorously for 2 minutes. Siphon out the aqueous layer (upper) and discard. Add 10 ml. of water to the residual chloroform solution, shake for 2 minutes and siphon out again the aqueous layer. Repeat the washing twice with 10-ml. portions of water. Measure fluorescence of the chloroform solution by a photoelectric fluorometer (Kotaki, model SKM 4) with quinine sulfate (0.05 mg./l.) as a standard.
Calculations. Correct the fluorescence value by subtracting the fluorescence value for reagent blank. Obtain [xg. of Beclotiamine corresponding to corrected fluorescence from standard curve.
Standard curve was prepared as follows: apply 0.5 [jig. and 1.0 \t,g. of Beclotiamine hydrochloride each dissolved in 5 ml. of 0.05 M acetate buffer, pH 4.5, to the Decalso columns and proceed as in the determination.
Beclotiamine content was expressed as equivalent to p.p.m., Beclotiamine hydrochloride in wet weight of tissues or egg yolks.
Under the conditions described, the effect of thiamine upon apparent Beclotiamine content was less than 0.5% of the original amounts of thiamine. This method gave a recovery of 80-90% of Beclotiamine added to the tissue homogenates, and tissue blank was less than 0.01 p.p.m.
Determination of thiamine in the presence of Beclotiamine. Because the technique of production and suggested reaction for converting Beclotiamine to chlorothiochrome is so similar to that of the thiamine-thiochrome relationship, it is conceivable that Beclotiamine might interfere in the thiamine assay by the thiochrome method. Therefore, in the presence of Beclotiamine, thiamine was determined by a modification of the thiochrome method. Beclotiamine was found labile at alkaline pH and was rapidly converted to a thiacyclobutane derivative (III) which produced no fluorophor by the addition of potassium ferricyanide ( Fig. 1) (Yonemoto, 1957) . This alkali-labile property of Beclotiamine was employed in the thiamine determination in the presence of Beclotiamine. The procedure is as follows: transfer the residual effluent solution (5 ml.) from the Decalso column to a 50-ml. brown-glass tube, and add 5 ml. of water and 1 ml. of 1% cysteine solution to the tube. Adjust to pH 12 by the addition of 2 N NaOH and an alkaline glycine solution (a mixture of 1 part of 1 M glycine and 2 parts of 2 N NaOH) using a glass electrode pH meter and let stand for 20 minutes at room temperature. Add 2 N HC1 to give pH 1-2. Under the conditions specified, the alkali treatment destroys Beclotiamine but not thiamine.
Thiamine was, then, converted to thiochrome by cyanogen bromide and NaOH (Fujiwara and Matsui, 1953) . Add 3 ml. of cyanogen bromide solution, which was prepared by the addition of 10% KCN to icecold saturated bromine water until it was decolorized, mix gently, and let stand for 2 minutes. Add 3 ml. of 30% NaOH and mix. Immediately, add 12 ml. of w-butanol and 2-3 g. of anhydrous Na 2 S0 4 , shake vigorously for 2 minutes, and centrifuge at 1,000 r.p.m. for 1 minute. Pipet the butanol layer (upper) into a 15-ml. brown-glass tube, add 1-2 g. of anhydrous Na 2 S0 4 , and shake for 30 seconds. Measure the fluorescence of w-butanol solution by a photoelectric fluorometer with quinine sulfate (0.05 mg./l.) as a standard.
Cysteine was added to prevent the formation of thiamine disulfide from thiamine in the alkali conditions (Kawasaki and Horio, 1960) . Beclotiamine was completely destroyed by the alkali treatment, while 97 percent of thiamine was recovered from the treatment. Cyanogen bromide was employed in the thiochrome-forming reaction since the oxidation with potassium ferricyanide was strongly inhibited by cysteine.
SPECIFIC EXPERIMENTAL PROCEDURES AND RESULTS
(1) Residues in muscle and liver of chicken. Procedure: White Leghorn male chickens from a commercial hatchery were used. They were housed in electrically heated, thermostatically controlled battery brooders for the first 2 or 4 weeks and then transferred to growing units with raised wire floors. The chickens were fed the basal diet consisting of a mash of the following composition: corn, 56.0%; soya bean meal, 16.5%; tallow, 2.5%; wheat, 12.0%; fish meal, 7.5%; alfalfa meal, 2.5%; mineral and vitamins 3.0%. The diet contained thiamine at 6.6 mg. per kg. Beclotiamine naphthalene disulfonate (NDS) was supplemented to the basal diet at the levels of 0.0125%, 0.05%, and 0.10% in feed (equivalent to Beclotiamine hydrochloride 0.0075%), 0.030%, and 0.060% in feed, respectively 2 ). The medicated diets and water were fed ad libitum to the chickens.
Experiments were of two types: (1) preliminary investigations feeding Beclotiamine-NDS 0.0125% in the diet for 4 weeks; (2) experiments of a more extensive nature feeding Beclotiamine-NDS 0.0125%), 0.05, and 0.10% in the diet for 8 weeks. In the preliminary experiments, thirty chickens, two weeks-old, were fed the Beclotiamine medicated diet for 4 weeks and then fed the non-medicated diet for 3 days. Five birds were sacrificed each on the 7th, 14th, and 28th day on medication and on the 1st, 2nd, and 3rd day after withdrawal of the medicated diet for exam-ination of Beclotiamine residues in the muscle (breast) and liver. In the more extensive experiments, one hundred chickens, a day-old, were divided into 4 equal groups of 25 birds each. The first, second, and third group received Beclotiamine-NDS 0.0125%, 0.05%), and 0.10% in feed, respectively, and the fourth group remained as control without any treatment. The chickens were fed the medicated diets for a period of 8 weeks and then fed the nonmedicated diet for 4 days. All chickens were weighed individually at 4 and 8 weeks. Feed consumption data were recorded over the entire 8-week test period. Five birds from each treatment and control group were sacrificed on the 28th, 42nd, and 56th day on medication and on the 1st and 4th day off medication, analyzed for Beclotiamine residues in the muscle (breast) and liver and for total thiamine concentrations in the liver, selected organs were weighed, and serum was subjected to the biochemical tests. Histological examination of sections of liver was also carried out by staining with hematoxylin-eosin-phosphomolybdic acid.
Results: When the chickens were fed Beclotiamine-NDS at the level of 0.0125% in feed, a recommended dose for use as coccidiostat, the Beclotiamine residues in the muscle tissue remained in low concentrations of 0.05 p.p.m. to 0.08 p.p.m. during the feeding of the coccidiostat for 28 days (Table 1) . After withdrawal of Beclotiamine from the diet the drug concentration in the muscle immediately decreased and reached to 0.01 p.p.m. by the third day. Beclotiamine was found approximately 0.5 p.p.m. in the liver, however, the levels rapidly decreased after its withdrawal from the diet; in the first 24 hours off medication the levels declined to about 13% of the initial concentration and continued to decrease to 0.03 p.p.m. on the third day.
No accumulation of Beclotiamine and its rapid elimination from the tissues observed in the previous 4-week study prompted further investigation as to the effect of the drug on chickens when fed in the diet at elevated levels for a prolonged period. As shown in Table 2 and 3, feeding of 0.05% and 0.10% Beclotiamine-NDS in feed resulted in the Beclotiamine concentrations in the muscle about 0.1 p.p.m. and 0.2 p.p.m., and in the liver about 0.8 p.p.m. and 1.4 p.p.m., respectively, and these levels were essentially unchanged during 56 days of the medication. When Beclotiamine was withdrawn from the feed at the end of 56 days, the levels in the muscle decreased rapidly to 0.02 p.p.m. and 0.03 p.p.m., and in the liver decreased to 0.09 p.p.m. and 0.14 p.p.m., respectively, in 24 hours. After 4 days the levels no higher than 0.02 p.p.m. in the muscle and 0.04 p.p.m. in the liver were found in all the groups.
Total thiamine concentrations in the liver were measured in the birds on the 42nd and 56th day on medication and on the 1st and 4th day off medication, and these values were compared with those in the birds fed the non-medicated diet. As shown in Table 4 , total thiamine concentrations in the liver were all approximately 4 p.p.m. and appeared to show no decrease by feeding of Beclotiamine-NDS up to 0.10% in feed. Withdrawal of the medication also did not affect the thiamine concentrations in the liver.
The growth, feed conversion and mortality data are shown in Table 5 , after both 28 and 56 days' consecutive feeding of Beclotiamine. No adverse effects were noted in all the groups administered Beclotiamine for either 28 or 56 days based on weight gain, feed efficiency or mortality data, compared to the controls. Weights of selected organs (liver, kidney, heart, spleen, adrenal testis, and brain) showed no change by feeding of Beclotiamine for 56 days (Table   TABLE 4 Beginning weights of the chickens were 36 g. * Ten birds were sacrificed on 28th and 42nd day for examination of the drug residues. 6). Alkali phosphatase, glutamic-pyruvic and glutamic-oxalacetic transaminase activities in serum of the chickens showed no differences between the Beclotiamine treated group and the control group (Table  7) . The concentrations of glucose, protein, and total cholesterol in serum of the chickens were also not effected by feeding of Beclotiamine. No histopathological lesions in the liver were observed which could be solely related to Beclotiamine treatment when compared to the tissue sections from the control chickens.
(2) Residues in egg yolk. Procedure: Six White Leghorn hens were housed in wirefloored batteries within a constant temperature room of 22 ± 2°C. Medicated ration was prepared from commercial breeder ration to which Beclotiamine-NDS was Average of 5 chickens (mean + S.E.). 1 Alkali phosphatase was determined by the method of Kind and King (1954) .
2 Glutamic-pyruvic and glutamic-oxalacetic transaminases were determined by the method of Rietman and Frankel (1957). added at the level of 0.05%, 4 times the use level. The hens were fed the medicated diet ad libitum for 14 days and then fed the non-medicated diet for 18 days. Eggs were collected daily from the hens and the yolks and whites were analyzed individually for Beclotiamine.
Results: Fig. 2 shows the curve obtained for Beclotiamine concentrations in egg yolks during and following treatment of laying hens with the drug in feed. When hens were given feed containing 0.05% Beclotiamine-NDS they produced yolks containing Beclotiamine on the 4th day of treatment. The concentration of the drug increased rapidly from then on and reached maximum value of approximately 0.9 p.p.m. by the 12th day. Upon withdrawal of the medication from the feed there was a two or three-day lag before yolk concentrations began to decline precipitously. The concentrations reached non-detectable levels of less than 0.01 p.p.m. by the 15th day after withdrawal of the Beclotiamine diet. Essentially, no Beclotiamine was detected in egg white.
DISCUSSION
The chemical properties of Beclotiamine resembled to those of thiamine: Beclotiamine was eluted from a Decalso column together with thiamine and produced a fluorophor, chlorothiochrome, in the same conditions as thiamine. However, after conversion to chlorothiochrome and thiochrome, these compounds were separated from each other by difference in their solubilities in chloroform. Since no appreciable interference from thiamine was noted in the analysis of Beclotiamine, this method could be used for the determination of Beclotiamine in chicken muscle, liver, and egg yolk.
Beclotiamine was degraded into a thiacyclobutane derivative by the alkali treatment. The conversion to the thiacyclobutane derivative rapidly occurred in pH higher than 10.5. Eighty-four percent of Beclotiamine was converted to the thiochrome-negative compound at pH 12 in 30 seconds. Therefore, care must be taken not to bring pH of the extract to alkali in the Beclotiamine determination.
Beclotiamine concentrations did not increase in the muscle tissue and liver in spite of the continued feeding of the drug at the use level (0.0125%) and at the elevated levels (0.05% and 0.10%) in the diet for 8 weeks, indicating that no accumulation of the coccidiostat occurs in the chicken tissues.
Beclotiamine concentration was rapidly decreased in the tissues after withdrawal of the medication. However, metabolites as degradation products of Beclotiamine should be also considered during analysis. Although the metabolism of Beclotiamine in chicken tissues has not yet been clarified, Sahashi et al. (1969) reported that after oral administration of Beclotiamine-35 S to an operated bird having an artificial anus, 82% of the radioactivity-35 S was recovered in urine and 18% in feces and that most of the radioactivity (76%) was excreted in urine in 12 hours. These results provided the evidence that Beclotiamine and its metabolites were rapidly eliminated from the body.
Beclotiamine did not decrease the total thiamine concentration in the liver by its continuous feeding to chickens in the present experiments. Although the antithiamine activity of Beclotiamine was demonstrated on the growth of Lactobacillus jermenti and Kloeckera apiculata (Hiraoka and Shimada, 1961) , Katano et al. (1970) failed to detect the antithiamine activity of Be-clotiamine to rats or chickens. They reported that orally administered Beclotiamine showed no counteraction to the growth increment induced by a definite amount of thiamine (100 ng./kg. body weight/day) at the ratio of Beclotiamine to the vitamin from 100 to 1,000. Therefore, Beclotiamine was thought to be a thiamine analogue having very weak antithiamine activity to chickens or rats.
Feeding of 0.10% Beclotiamine-NDS (8 times the use level) in the diet for 8 weeks resulted in normal performance, based on growth, feed conversion, mortality, organ weights, biochemical data on serum, and histological examination of the liver. On the basis of the above findings it may state that administration of Beclotiamine-NDS 0.10% in feed for 56 consecutive days produced no toxic effects in growing chickens.
Beclotiamine was detected in egg yolk but not in egg white when the coccidiostat was fed to laying hens. Polin et al. (1968) reported that Amprolium, a thiamine analogue coccidiostat, was also detected only in egg yolk but not in white. Beclotiamine was reported to have no effect on egg production, hatchability, and fertility of egg at the dose of 0.0125% in the diet (Takahashietal.,1961) .
SUMMARY
A fluorometric method for the analysis of Beclotiamine, a coccidiostat, in tissues and egg yolks is presented.
The Beclotiamine residues were determined by the method in the muscle tissue, liver, and egg yolk following oral administration of Beclotiamine to chickens or laying hens. Beclotiamine was detected at about 0.06 p.p.m. and 0.5 p.p.m. in the muscle and liver, respectively, of chickens fed the drug at the use level (0.0125% Beclotiamine-naphthalene disulfonate (NDS) ) for 8 weeks. Beclotiamine rapidly disappeared from the tissues once the compound was withdrawn from the diet. On the 4th day after withdrawal, Beclotiamine was almost undetected in the tissues. Even when the dose of Beclotiamine was increased to four (0.05%) to eight (0.10%) times greater, no accumulation of the drug occurred in the tissues throughout the entire 8 weeks of the medication. When Beclotiamine was fed to laying hens at 4 times the use level, Beclotiamine concentrations averaging 0.8 p.p.m. in egg yolk were reached by day 12 on medication and the drug was no longer detected in yolk by the 15th day after withdrawal. Beclotiamine was not detected in egg white.
The toxicity and safety of Beclotiamine was studied in the chickens. Total thiamine concentrations in the liver were not decreased by the feeding of the drug. No adverse effects were noted in the birds based on weight gain, feed efficiency, organ weights, biochemical data on serum and histological examination of the liver by the administration of Beclotiamine-NDS up to 0.10% in feed.
T HE wide variety of commercially availble phosphorus supplements which frequently change in analysis and availability require constant research effort in order to provide accurate information for formulation purposes. Many factors have been shown to influence the biological availability of these materials. Gillis et al. (1948) indicated that availability differences were largely due to variations in the content of metaphosphate and pyrophosphate. These compounds are primarily calcium metaphosphate and calcium pyrophosphate
